±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 2293  |  »Ø¸´: 12
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

yalefield

½ð³æ (ÎÄ̳¾«Ó¢)

ÀϺºÒ»Ã¶

[½»Á÷] ÏÈÉùÒ©ÒµµÄ¶÷¶È£¨ENDOSTAR£©[ת]

×÷ÕߣºJingyi

¡¡¡¡2007Äê³õ£¬ÖйúµÄÒ»¼ÒÖÆÒ©¹«Ë¾ÏÈÉùÖÆÒ©ÔÚŦԼÉÏÊС£ÆäÖ÷Òª²úÆ·ÊÇ¡°¶÷¶È¡±(ENDOSTAR)£¬Ò»ÖÖÒÖÖÆÑª¹ÜÉú³¤µÄÒ©ÎÖ÷ÒªÕë¶Ô·ÇСϸ°û·Î°©(NSCLC)¡£ÕâÊÇÒ»Öַdz£ÆÕ±éµÄ¶ñÐÔÖ×Áö£¬¾­³£ÓÉÎüÑÌÓÕ·¢¡£

¡¡¡¡¼ÇµÃÒÔǰ¿´¹ýһЩÎÄÕ£¬½éÉÜͨ¹ýÒÖÖÆÑª¹ÜÉú³¤¡°¶öËÀ¡±°©Ï¸°û¡£Ã»Ïëµ½ÏÖÔÚÒѾ­³ö²úÆ·£¬¶øÇÒÊÇÕë¶ÔÖйú·Ç³£ÆÕ±éµÄ·Î°©¡£¿Éϲ¿ÉºØ¡£

¡¡¡¡µ«ÊÇ×ÐϸÑо¿Ò»Ï£¬È´·¢ÏÖÎÊÌâ¡£

    ¶÷¶ÈµÄÖ÷Òª³É·Ö(Endostatin)ÔÚ¹úÍâµÄ¶þÆÚÁÙ´²Öб»Åж¨Ã»ÓÐÃ÷ÏÔЧ¹û¡£(Note 1) µ±³õÑо¿¸ÃÒ©µÄÒ»¼ÒÃÀ¹úÉú»¯¹«Ë¾EntreMed¼¸ºõÆÆ²ú¡£²Æ¸»ÔÓÖ¾ÆÀÂÛ˵£¬¸ÃÒ©¡°Ï·¾çÐÔµÄʧ°ÜÁË¡±¡£(Note 2)
    µ«ÊÇ£¬¸Ã¹«Ë¾ÔÚÖйú×öµÄ493ÀýÈ´·¢ÏÖʹÓö÷¶È¿ÉÒÔʹ1ÄêÉú´æÂÊ´Ó31%Ôö¼Óµ½63%£¬Æ½¾ùÉú´æÊÙÃüÊǶÔÕÕ×éµÄ5±¶¡£(Note 3£©¡£

¡¡¡¡ÏÖÔÚ¶÷¶ÈÒѾ­ÔÚÖйú500¶à¼ÒҽԺʹÓã¬ÓÃÓÚÖÎÁÆÖйú´óÁ¿ÒòÎüÑ̶øµÃ·Î°©µÄ²¡ÈË¡£ºÜÆæ¹ÖΪʲô¹úÄÚÍâµÄÁÙ´²½á¹û²îÒìÕâô´ó¡£ÓÐûÓÐÄÄλרҵÈËÊ¿Ñо¿Ò»Ï¡£

Note:
1. Kulke M H et al (2006). "Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors". J. Clin. Oncol. 24: 3555-3561.
2. http://yalemedicine.yale.edu/ym_sp06/booksideas.html
3. Company Prospectus - Strong Growth Potential of Our Innovative Pharmaceutical Endu
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

¶¹¸ç

Ö÷¹ÜÇø³¤ (Ö°Òµ×÷¼Ò)

ÖÆÁ£ÄÜÊÖ

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

ÕâÑùµÄ»°Ò©ÎïûÓÐÁÆÐ§ÔõôÄÜÒ»Ö±ÔÚÁÙ´²ÉÏÓÃÄØ£¿
±ßѧ±ßÎÊ£¬²ÅÓÐѧÎÊ¡£
3Â¥2007-12-19 14:00:23
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 13 ¸ö»Ø´ð

wangw2008

½ð³æ (Ö°Òµ×÷¼Ò)

´¿½àÔÚ¼ËÔº,¶éÂäÔÚ½ÌÓý²¿.

±¾ÈËÒ²Ò»Ö±ÔÚ»³ÒÉÕâ¸öÊý¾Ý£¬ÏÈÉùµÄËÄÆÚÁÙ´²Êý¾Ý×öµÄºÜ²î£¬ÖÁÓÚ£±£¬£²ÆÚµÄÊý¾ÝÔõôÀ´µÄ£®´ó¸ÅÖ»ÓÐÖйúµÄÕâ¸ö»·¾³Ï²Żá³öÏÖ£®
ÑÏÕýÉùÃ÷: ±¾ÌûÄÚÈÝÎ´Éæ¼°¹¥»÷ÈκγæÓÑ(°üÀ¨ÒÔָɣÂî»±£¬º¬É³ÉäÓ°µÈÐÎʽ),²»Ó°ÏìºÈѪ(ɽ¶«»°ºÍг)
2Â¥2007-12-19 07:07:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
4Â¥2007-12-19 14:13:57
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
5Â¥2007-12-19 15:05:12
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +8 ¸ï΢¹ð 2026-04-04 8/400 2026-04-04 23:36 by lqwchd
[¿¼ÑÐ] Çóµ÷¼Á +7 xzghyuj 2026-04-04 7/350 2026-04-04 22:25 by oooqiao
[¿¼ÑÐ] 085404×Ü·Ö289£¬Çóµ÷¼Á +4 Acesczlo 2026-03-29 4/200 2026-04-04 21:43 by hemengdong
[¿¼ÑÐ] 278Çóµ÷¼Á +3 ÒÀ¾É£¡ 2026-04-02 4/200 2026-04-04 20:27 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 277¹¤¿ÆÇóµ÷¼Á +7 1915668 2026-04-04 7/350 2026-04-04 17:21 by °¡¿¡£¡
[¿¼ÑÐ] 0703Çóµ÷¼Á +6 zizimo 2026-03-31 6/300 2026-04-04 14:16 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] ÇóÉúÎïѧרҵµ÷¼Á-332·Ö +5 ÔÆ¶äåÞÍäÖ¸ÄÏ 2026-04-04 5/250 2026-04-04 10:05 by rzh123456
[¿¼ÑÐ] Çóµ÷¼Á +4 ѹÁ¦??´ó 2026-04-03 4/200 2026-04-03 21:36 by à£à£à£0119
[¿¼ÑÐ] µ÷¼ÁÇóÖú +8 Ïë»»ÊÖ»ú²»Ïë½âÊ 2026-04-02 11/550 2026-04-03 14:16 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] ÊýÒ»Ó¢Ò»285Çóµ÷¼Á +7 AZMK 2026-04-03 9/450 2026-04-03 13:03 by ms629
[¿¼ÑÐ] 283Çóµ÷¼Á +3 jiouuu 2026-04-02 4/200 2026-04-02 14:08 by ßÕßÕßÕßÉßÉßÉ
[¿¼ÑÐ] Ò»Ö¾Ô¸±±¾©¿Æ¼¼´óѧ²ÄÁÏѧ˶328·ÖÇóµ÷¼Á +6 1¶Îʱ¼ä 2026-03-31 7/350 2026-04-02 13:57 by 3041
[¿¼ÑÐ] Ò»Ö¾Ô¸ÏÃÃÅ´óѧ»¯Ñ§¹¤³Ì£¨×¨Ë¶£©-Êý¶þÓ¢¶þ406·Ö-Çóµ÷¼Á +5 Ïô󻯹¤ 2026-04-01 5/250 2026-04-02 10:03 by jp9609
[¿¼ÑÐ] Ò»Ö¾Ô¸°²»Õ´óѧ¼ÆËã»ú¿ÆÑ§Óë¼¼Êõѧ˶£¬331·ÖÇóµ÷¼Á +5 ½¯²ýÅôqtj 2026-04-01 5/250 2026-04-02 08:10 by fxue1114
[¿¼ÑÐ] 085600 Ò»Ö¾Ô¸9 ×Ü·Ö351 Çóµ÷¼ÁѧУ +7 czhcz 2026-03-31 9/450 2026-04-01 19:24 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] Çó0861½»Í¨ÔËÊäר˶or²ÄÁÏר˶µ÷¼Á +4 ÀÕ²¼ÀÊ@ 2026-03-31 4/200 2026-04-01 09:54 by Ò»Ö»ºÃ¹û×Ó?
[¿¼ÑÐ] Çóµ÷¼Á£ºÒ»Ö¾Ô¸£ºÄϾ©´óѧ רҵ£º0705 ×Ü·Ö320 £¬±¾¿Æ985£¬ËÄÁù¼¶Òѹý +3 lfy760306 2026-03-31 3/150 2026-04-01 01:57 by Creta
[¿¼ÑÐ] 254²ÄÁÏÓ뻯¹¤Çóµ÷¼Á +3 º²¶¬ÁÖéª 2026-03-30 4/200 2026-03-31 17:53 by yishunmin
[¿¼ÑÐ] Ó¢Ò»ÊýÒ»×Ü·Ö334Çóµ÷¼Á +4 ³ÂÑôÀ¤ 2026-03-31 4/200 2026-03-31 14:22 by ¼Çʱ¾2026
[¿¼ÑÐ] ¼ª´óÉúÎïѧ326·ÖÇóµ÷¼Á +3 sunnyupup 2026-03-31 3/150 2026-03-31 09:28 by longlotian
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û